Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Vered Schechner is active.

Publication


Featured researches published by Vered Schechner.


Antimicrobial Agents and Chemotherapy | 2010

National Multicenter Study of Predictors and Outcomes of Bacteremia upon Hospital Admission Caused by Enterobacteriaceae Producing Extended-Spectrum β-Lactamases

Dror Marchaim; Tamar Gottesman; Orna Schwartz; Maya Korem; Yasmin Maor; Galia Rahav; Rebekah Karplus; Tsipora Lazarovitch; Eyal Braun; Hana Sprecher; Tamar Lachish; Yonit Wiener-Well; Danny Alon; Michal Chowers; Pnina Ciobotaro; Rita Bardenstein; Alona Paz; Israel Potasman; Michael Giladi; Vered Schechner; Mitchell J. Schwaber; Shiri Klarfeld-Lidji; Yehuda Carmeli

ABSTRACT Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae are pathogens that may lead to a spectrum of clinical syndromes. We aimed to identify predictors and outcomes of ESBL bacteremia upon hospital admission (UHA) in a nationwide prospective study. Thus, a multicenter prospective study was conducted in 10 Israeli hospitals. Adult patients with bacteremia due to Enterobacteriaceae diagnosed within 72 h of hospitalization were included. Patients with ESBL producers (cases) were compared to those with non-ESBL producers (controls), and a 1:1 ratio was attempted in each center. A case-control study to identify predictors and a cohort study to identify outcomes were conducted. Bivariate and multivariate logistic regressions were used for analyses. Overall, 447 patients with bacteremia due to Enterobacteriaceae were recruited: 205 cases and 242 controls. Independent predictors of ESBL were increased age, multiple comorbid conditions, poor functional status, recent contact with health care settings, invasive procedures, and prior receipt of antimicrobial therapy. In addition, patients presenting with septic shock and/or multiorgan failure were more likely to have ESBL infections. Patients with ESBL producers suffered more frequently from a delay in appropriate antimicrobial therapy (odds ratio [OR], 4.7; P, <0.001) and had a higher mortality rate (OR, 3.5; P, <0.001). After controlling for confounding variables, both ESBL production (OR, 2.3; P, 9.1) and a delay in adequate therapy (OR, 0.05; P, 0.001) were significant predictors for mortality and other adverse outcomes. We conclude that among patients with bacteremia due to Enterobacteriaceae UHA, those with ESBL producers tend to be older and chronically ill and to have a delay in effective therapy and severe adverse outcomes. Efforts should be directed to improving the detection of patients with ESBL bacteremia UHA and to providing immediate appropriate therapy.


Emerging Infectious Diseases | 2017

Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel

Ronen Ben-Ami; Judith Berman; Ana Novikov; Edna Bash; Yael Shachor-Meyouhas; Shiri Zakin; Yasmin Maor; Jalal Tarabia; Vered Schechner; Amos Adler; Talya Finn

Clinical features and experimentally deduced virulence indicate that C. auris has the greater lethal potential.


Antimicrobial Agents and Chemotherapy | 2010

Treatment with Fluoroquinolones or with β-Lactam-β-Lactamase Inhibitor Combinations Is a Risk Factor for Isolation of Extended-Spectrum-β-Lactamase-Producing Klebsiella Species in Hospitalized Patients

Kenneth Wener; Vered Schechner; Howard S. Gold; Sharon B. Wright; Yehuda Carmeli

ABSTRACT Antibiotic exposure exerts strong selective pressure and is an important modifiable risk factor for antibiotic resistance. We aimed to identify the role of various antibiotics as risk factors for the isolation of extended-spectrum-β-lactamase (ESBL)-producing Klebsiella spp. in hospitalized patients at a tertiary-care hospital. A parallel multivariable model was created to compare two groups of cases with either nosocomially acquired ESBL- or non-ESBL-producing Klebsiella spp. to a common control group of hospitalized patients (a case-case-control design). Seventy-eight ESBL cases, 358 non-ESBL cases, and 444 controls were analyzed. Significant factors associated with the isolation of Klebsiella spp. were an age of >65 years, transfer from a health care facility, an intensive care unit (ICU) stay, and the presence of a comorbid malignancy or lung, hepatic, or renal disease. A propensity score was generated from the above, and our ability to discriminate between Klebsiella cases and controls (area under the receiver-operating-characteristic [ROC] curve, 0.78) was good. The ESBL phenotype was tightly linked with fluoroquinolone resistance (95% versus 18%, P < 0.001). Factors associated with isolation of ESBL Klebsiella spp. in a multivariable analysis, adjusting for the propensity score, included exposure to β-lactam-β-lactamase inhibitor combinations (odds ratio [OR], 10.17; 95% confidence interval [CI], 1.19 to 86.92) and to fluoroquinolones (OR, 2.86; 95% CI, 1.37 to 5.97). Exposure to broad-spectrum cephalosporins was statistically associated with ESBL Klebsiella spp. only among the subgroup of patients not treated with fluoroquinolones. In our institution, where the ESBL-producing-Klebsiella phenotype is coselected with fluoroquinolone resistance, fluoroquinolone and β-lactam-β-lactamase inhibitor combinations, rather than cephalosporins, are the main risk factors for ESBL isolates. Formulary interventions to limit the spread of ESBL-producing isolates should be tailored to each setting.


Infection Control and Hospital Epidemiology | 2016

Risk Factors for Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae (CP-CRE) Acquisition Among Contacts of Newly Diagnosed CP-CRE Patients.

Anat Schwartz-Neiderman; Tali Braun; Noga Fallach; David A. Schwartz; Yehuda Carmeli; Vered Schechner

OBJECTIVE Carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CP-CRE) are extremely drug-resistant pathogens. Screening of contacts of newly identified CP-CRE patients is an important step to limit further transmission. We aimed to determine the risk factors for CP-CRE acquisition among patients exposed to a CP-CRE index patient. METHODS A matched case-control study was performed in a tertiary care hospital in Israel. The study population was comprised of patients who underwent rectal screening for CP-CRE following close contact with a newly identified CP-CRE index patient. Cases were defined as positive tests for CP-CRE. For each case patient, 2 matched controls were randomly selected from the pool of contacts who tested negative for CP-CRE following exposure to the same index case. Bivariate and multivariate analyses were conducted using conditional logistic regression. RESULTS In total, 53 positive contacts were identified in 40 unique investigations (896 tests performed on 735 contacts) between October 6, 2008, and June 7, 2012. bla KPC was the only carbapenemase identified. In multivariate analysis, risk factors for CP-CRE acquisition among contacts were (1) contact with an index patient for ≥3 days (odds ratio [OR], 9.8; 95% confidence interval [CI], 2.0-48.9), (2) mechanical ventilation (OR, 4.1; 95% CI, 1.4-11.9), and (3) carriage or infection with another multidrug-resistant organism (MDRO; OR, 2.6; 95% CI, 1.0-7.1). Among patients who received antibiotics, cephalosporins were associated with a lower risk of acquisition. CONCLUSIONS Patient characteristics (ventilation and carriage of another MDRO) as well as duration of contact are risk factors for CP-CRE acquisition among contacts. The role of cephalosporins requires further study. Infect Control Hosp Epidemiol 2016;1-7.


Therapeutic Apheresis and Dialysis | 2004

Comparative Analysis Between Dextran Sulfate Adsorption and Direct Adsorption of Lipoproteins in their Capability to Reduce Erythrocyte Adhesiveness/Aggregation in the Peripheral Blood

Vered Schechner; Shlomo Berliner; Itzhak Shapira; Daniel Justo; Tiberiu Hershcovici; David Zeltser; Yitzhak Beigel

Abstract: The purpose of this study was to compare the degree of erythrocyte adhesiveness/aggregation (EAA) reduction of two low‐density lipoprotein (LDL) apheretic procedures, namely direct adsorption of lipoproteins (DALI) and dextran sulfate adsorption (DSA). A significant (Pu2003<u20030.001) reduction of EAA was noted in six hypercholesterolemic patients who underwent a total of 40 apheretic sessions and no difference was noted in the degree of EAA reduction by the two techniques. Thus, being a real‐time and point‐of‐care test, the erythrocyte adhesiveness/aggregation test can be applied in relevant situations of acute ischemia, where therapeutic LDL apheresis could improve the hemorheology of individuals with increased concentrations of cholesterol and inflammatory sensitive proteins.


Therapeutic Apheresis and Dialysis | 2005

Plasma dependent reduction in red blood cell aggregation after dextran sulfate low-density lipoprotein apheresis--implications for rheological studies.

Vered Schechner; Ronen Ben-Ami; Tiberiu Hershcovici; Shaul Yedgar; Ytzhak Beigel; Itzhak Shapira; Shlomo Berliner; Gershon Barsthein

Abstract:u2002 Red blood cell (RBC) aggregation is increased in familial hypercholesterolemia, and is reduced significantly after low density lipoprotein (LDL) apheresis. The purpose of the present study was to clarify whether this reduction depends on changes in plasma composition, RBC membrane properties, or both. RBC aggregation was determined in a computerized cell flow‐properties analyzer, before and after LDL apheresis. We compared RBC aggregation in autologous plasma with aggregation in a plasma‐free standard solution (0.5% of dextran 500u2003kDa) to define the separate contributions of plasma and cellular properties to the observed RBC aggregation. RBC aggregation in autologous plasma was reduced by 35.5% after LDL apheresis (Pu2003=u20030.01) but was not significantly affected when measured in dextran 500. This suggests that LDL apheresis attenuated RBC aggregation by altering plasma composition rather than RBC membrane properties. These results are relevant to the understanding of hemorheological changes which follow therapeutic apheresis in hypercholesterolemic patients.


The Journal of pharmacy technology | 2003

Rhabdomyolysis Due to Combined Therapy with Cerivastatin and Diclofenac

Vered Schechner; Tiberiu Hershcovici; Yitzhak Beigel

Objective: To describe the occurrence of severe rhabdomyolysis and acute renal failure in a patient treated concomitantly with cerivastatin and diclofenac. Case Summary: A 73-year-old white man with mild chronic renal failure, treated with cerivastatin for hypercholesterolemia, received intramuscular injections of diclofenac for low-back pain. A few days later, severe muscle weakness and acute renal failure developed. Laboratory tests confirmed severe rhabdomyolysis. Diclofenac and cerivastatin were discontinued, and treatment with forced diuresis and urine alkalinization was started. Twenty-four days later, serum creatine phosphokinase and urinary function returned to baseline, and the muscle weakness improved. Discussion: Rhabdomyolysis is a well-known adverse effect of statins. According to recent reports, it occurs more frequently with cerivastatin than with other statins. Nevertheless, the interaction between cerivastatin (or other statins) and diclofenac as a trigger for rhabdomyolysis has never been reported. Conclusions: Coadministration of diclofenac (and perhaps other nonsteroidal antiinflammatory drugs) with cerivastatin (and perhaps other statins) should be done cautiously, especially in the presence of renal failure, under close monitoring of renal function and muscle enzyme levels.


PLOS ONE | 2017

A mathematical model of Clostridium difficile transmission in medical wards and a cost-effectiveness analysis comparing different strategies for laboratory diagnosis and patient isolation

Vered Schechner; Yehuda Carmeli; Moshe Leshno; Gayatri Vedantam

Background Clostridium difficile infection (CDI) is a common and potentially fatal healthcare-associated infection. Improving diagnostic tests and infection control measures may prevent transmission. We aimed to determine, in resource-limited settings, whether it is more effective and cost-effective to allocate resources to isolation or to diagnostics. Methods We constructed a mathematical model of CDI transmission based on hospital data (9 medical wards, 350 beds) between March 2010 and February 2013. The model consisted of three compartments: susceptible patients, asymptomatic carriers and CDI patients. We used our model results to perform a cost-effectiveness analysis, comparing four strategies that were different combinations of 2 test methods (the two-step test and uniform PCR) and 2 infection control measures (contact isolation in multiple-bed rooms or single-bed rooms/cohorting). For each strategy, we calculated the annual cost (of CDI diagnosis and isolation) for a decrease of 1 in the average daily number of CDI patients; the strategy of the two-step test and contact isolation in multiple-bed rooms was the reference strategy. Results Our model showed that the average number of CDI patients increased exponentially as the transmission rate increased. Improving diagnosis by adopting uniform PCR assay reduced the average number of CDI cases per day per 350 beds from 9.4 to 8.5, while improving isolation by using single-bed rooms reduced the number to about 1; the latter was cost saving. Conclusions CDI can be decreased by better isolation and more sensitive laboratory methods. From the hospital perspective, improving isolation is more cost-effective than improving diagnostics.


Journal of Clinical Apheresis | 2004

Effect of different LDL-apheresis methods on parameters involved in atherosclerosis

Tiberiu Hershcovici; Vered Schechner; Jerome Orlin; Daniella Harell; Yitzhak Beigel


Thrombosis Research | 2004

The degree of red blood cell aggregation on peripheral blood glass slides corresponds to inter-erythrocyte cohesive forces in laminar flow

Shlomo Berliner; Ronen Ben-Ami; Dorit Samocha-Bonet; Subchi Abu-Abeid; Vered Schechner; Yitzhak Beigel; Itzhak Shapira; Saul Yedgar; Gershon Barshtein

Collaboration


Dive into the Vered Schechner's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Itzhak Shapira

Tel Aviv Sourasky Medical Center

View shared research outputs
Top Co-Authors

Avatar

Ronen Ben-Ami

Tel Aviv Sourasky Medical Center

View shared research outputs
Top Co-Authors

Avatar

Shlomo Berliner

Tel Aviv Sourasky Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Howard S. Gold

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge